Blood substitute composition and method of use

Patent metadata

Field	Value
Publication number	US-9655952-B2
Application number	US-201615232298-A
Country	US
Kind code	B2
Filing date	Aug 9, 2016
Priority date	May 3, 2013
Publication date	May 23, 2017
Grant date	May 23, 2017

Abstract

The present disclosure provides oxygen-carrying nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to carry oxygen in blood.

First claim

What is claimed is:

1. A process for the preparation of a nanoparticle, the nanoparticle having a substantially bi-concaved disc shape, wherein the nanoparticle comprises an aqueous core, a bi-layered shell comprising an amphiphilic polymer, and a payload comprising an oxygen-carrying agent, an allosteric effector, and a reducing agent; the process comprising:
(a) hydrophobically modifying a branched polymer by covalently conjugating lipids to at least 25% of the free reactive groups of the branched polymer to form an amphiphilic polymer;
(b) mixing the amphiphilic polymer with a non-polar solvent, and agitating the mixture to form a plurality of inverted micelles comprising the amphiphilic polymer;
(c) mixing the payload with a polar solvent and adding the payload mixture to the mixture from (b) to form a bi-phasic mixture, and agitating the bi-phasic mixture to transfer the payload to the inverted micelles; and
(d) agitating the inverted micelles comprising the payload in the presence of heat and an aqueous solvent to form the bi-concaved disc shaped nanoparticles comprising the payload.

2. The process of claim 1 , wherein the oxygen-carrying agent is synthetic hemoglobin or naturally occurring hemoglobin.

3. The process of claim 1 , wherein the allosteric effector is selected from the group consisting of 2,3-diphosphoglycerate (2,3-DPG), inositol hexaphosphate (IHP), pyridoxal-phosphate (PLP), and 2-[4-[[(3,5-dimethylanilino carbonyl]methyl]-phenoxy]-2-methylpropionic acid.

4. The process of claim 1 , wherein the reducing agent is selected from the group consisting of leucomethylene blue, glutathione and ascorbate.

5. The process of claim 1 , wherein the nanoparticle comprises about 3000 to about 10,000 hemoglobin molecules.

6. The process of claim 1 , wherein the nanoparticle comprises about 20% to about 60% (w/v) hemoglobin or about 30% to about 60% (w/v) hemoglobin.

7. The process of claim 1 , wherein the branched, amine-containing polymer is selected from the group consisting of a polyethyleneimine branched polymer, a PAMAM dendrimer, a star polymer, and a graft polymer.

8. The process of claim 1 , wherein the lipid is a fatty acid.

9. The process of claim 8 , wherein the fatty acid is selected from the group consisting of 10,12-pentacosadiynoic acid, hexadecyloctadecanoic acid, cholanic acid, linoleic acid, C24-pentacosadiynoic acid, and palmitic acid.

10. The process of claim 1 , wherein the amphiphilic polymer is further derivatized with polyethylene glycol, such that the nanoparticle has a zeta potential of about −15 mV to about +15 mV.

11. A method for increasing O 2 levels in a subject in need thereof, the method comprising administering to the subject an effective amount of an oxygen-carrying nanoparticle, wherein the nanoparticle has a substantially bi-concaved disc shape and comprises an aqueous core, a bi-layered shell comprising an amphiphilic polymer, and a payload; and wherein
the bi-layered shell has a hydrophilic outer layer, a hydrophilic inner layer, and a hydrophobic region between the hydrophilic outer layer and the hydrophilic inner layer;
the amphiphilic polymer comprises a branched, amine-containing polymer linked to a lipid; and
the payload comprises an oxygen-carrying agent, an allosteric effector, and a reducing agent.

12. The method of claim 11 , wherein the amphiphilic polymer comprising the hydrophilic outer layer of the shell is derivatized with polyethylene glycol, such that the particle has a zeta potential of about −15 mV to about +15 mV.

13. The method of claim 11 , wherein the average diameter of the nanoparticle is from about 150 nm to about 300 nm, and the average height of the nanoparticle is from about 30 nm to about 80 nm.

14. The method of claim 11 , wherein the oxygen-carrying agent is synthetic hemoglobin or naturally occurring hemoglobin.

15. The method of claim 11 , wherein the allosteric effector is selected from the group consisting of 2,3-diphosphoglycerate (2,3-DPG), inositol hexaphosphate (IHP), pyridoxal-phosphate (PLP), and 2-[4-[[(3,5-dimethylanilino carbonyl]methyl]-phenoxy]-2-methylpropionic acid.

16. The method of claim 11 , wherein the reducing agent is selected from the group consisting of leucomethylene blue, glutathione and ascorbate.

17. The method of claim 11 , wherein the nanoparticle comprises about 3000 to about 10,000 hemoglobin molecules.

18. The method of claim 11 , wherein the nanoparticle comprises about 20% to about 60% (w/v) hemoglobin or about 30% to about 60% (w/v) hemoglobin.

19. The method of claim 11 , wherein the nanoparticle limits the oxidation of hemoglobin to about 10% or less of the total concentration of hemoglobin in the nanoparticle.

20. The method of claim 11 , wherein the branched, amine-containing polymer is selected from the group consisting of a polyethyleneimine branched polymer, a PAMAM dendrimer, a star polymer, and a graft polymer.

Assignees

• Univ Washington

Inventors

• Lanza Gregory M
• Pan Dipanjan
• Doctor Allan
• Spinella Philip C

Classifications

• A61K38/063

  Glutathione · CPC title

• A61P7/08

  Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) · CPC title

• A61K9/51

  Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)} · CPC title

• A61K9/107

  Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)} · CPC title

• A61K9/0026

  Blood substitute; Oxygen transporting formulations; Plasma extender · CPC title